30 results
P
pediatric patients, adult patients
I/C
surgical interventions of the liver, imaging modalities
O
portal vein anatomy
P
patients with COVID-19
I/C
systematic review with meta-analysis, histopathological reports from deceased COVID-19 patients undergoing autopsy or liver biopsy
O
pooled prevalence estimates of liver histopathological findings: hepatic steatosis, congestion of hepatic sinuses, vascular thrombosis, fibrosis, Kupffer cell hyperplasia, portal inflammation, lobular inflammation, venous outflow obstruction, phlebosclerosis of the portal vein, herniated portal vein, periportal abnormal vessels, hemophagocytosis, and necrosis
P
liver resection patients
I/C
liver venous deprivation (LVD), portal vein ligation (PVL), portal vein embolization (PVE), associating liver partition and portal vein ligation for staged hepatectomy (ALPPS), different FLR modulation techniques
O
efficacy and perioperative safety
P
patients
I/C
femoral drilling techniques, standard transtibial (sTT), anteromedial portal (AMP), outside-in (OI), or modified transtibial (mTT) technique
O
side-to-side difference, Lachman test, pivot-shift test, International Knee Documentation Committee subjective and objective scores, Lysholm score, Tegner score
P
Asian population with portal hypertension
I/C
transjugular intrahepatic portosystemic shunt (TIPS), 8 mm vs 6-7 mm covered stents
O
post-TIPS hepatic encephalopathy (HE)
P
cirrhosis patients with (/without) portal vein thrombosis
I/C
anticoagulant therapy, control group
O
recanalization rate, thrombus progression, adverse events, death mortality
P
animals with chronic liver diseases
I/C
anticoagulant use
O
fibrosis scores, portal pressure, inflammatory activity, hepatic injury, animal survival
P
HCC patients
I/C
CEUS, CT and/or MRI
O
diagnostic value in differentiating between PVT and TIV
P
patients with gastric variceal bleeding (GV) due to portal hypertension
I/C
BRTO, TIPS
O
overall survival (OS) rate, imminent haemostasis rate, rebleeding rate, technical success rate, procedure complication rate (hepatic encephalopathy and aggravated ascites), Child-Pugh score
P
patients
I/C
TACE and I, control group
O
6-month, 12-month stent cumulative patency rate, 6-month, 12-month, 24-month overall survival rate, objective response rate of PVTT, main portal venous pressure changes, treatment-related adverse events